Global standards in API and Finished Dosage Forms (FDF)
Navigating Quality, Compliance, and Supply Chain Resilience in 2024-2026
Diclofenac Sodium remains one of the most widely utilized Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) globally. As a potent phenylacetic acid derivative, its primary mechanism involves the non-selective inhibition of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), effectively blocking prostaglandin synthesis. For global pharmaceutical buyers, procuring "Best Diclofenac Sodium Tablets" is not merely a transaction—it is a commitment to patient safety and therapeutic efficacy.
At Jiangxi Serum Pharma Industries Co., Ltd., we understand that "Information Gain" in procurement involves identifying suppliers who offer more than just a product. We provide integrated regulatory support, advanced formulation technology (like enteric coating and sustained-release matrices), and a transparent supply chain that mitigates the risks of API price volatility and quality inconsistency.
With nearly 10 years of export experience since our establishment in 2017, we hold deep expertise in biological products and Western medicines. Our "Best" status is backed by over 500 long-term clients who trust our GMP-certified facilities.
Leveraging China's robust chemical infrastructure, we ensure stable raw material sourcing. Our 200+ close-related suppliers allow us to maintain a consistent output of high-purity Diclofenac Sodium, meeting USP, BP, and IP pharmacopeia standards.
We monitor cutting-edge markets through customization services in Pre-Mix, Co-Crystallization, and Bio-Fermentation. This tech-driven approach ensures our tablets have superior bioavailability and stability.
Navigating the MOH (Ministry of Health) registration in Africa, Southeast Asia, and Latin America requires more than just a COA. We provide full CTD/eCTD dossiers, Stability Data, and GMP documentation to accelerate your local market entry.
Our Diclofenac Sodium Tablets are optimized for diverse clinical needs: Rheumatoid Arthritis, Osteoarthritis, acute musculoskeletal disorders, and post-operative pain management. We offer various strengths (25mg, 50mg, 100mg SR).
The market is shifting toward Green Manufacturing and Precision Dosage. We are investing in bio-fermentation pathways to reduce environmental impact and exploring co-crystallization to enhance the solubility of NSAIDs.
As a leading pharmaceutical and nutritional products supplier from China, Jiangxi Serum Pharma Industries Co., Ltd. bridges the gap between high-quality manufacturing and affordable pricing. Our portfolio includes biological products, vaccines, raw materials, intermediates, and plant extracts.
Beyond pharmaceuticals, we provide plant proteins (Mung Bean Protein) and probiotics to support holistic health balance and purity.
With annual sales exceeding $10M, our logistics network ensures temperature-controlled shipping and cold-chain integrity for sensitive products.
Addressing the critical needs of pharmaceutical buyers
A: Our products are manufactured strictly according to GMP standards and comply with BP (British Pharmacopoeia), USP (United States Pharmacopeia), and IP (International Pharmacopoeia) specifications, depending on the client's regional requirements.
A: Yes. We have a dedicated regulatory affairs team that provides full support for registration, including the provision of Free Sale Certificates (FSC), GMP certificates, and stability testing reports.
A: We offer Information Gain through our deep integration with 200+ raw material suppliers, ensuring we are the first to know about market shifts. Our expertise in Pre-Mix and Co-Crystallization allows us to offer superior formulation quality at competitive Chinese factory prices.
A: For standard formulations, our lead time is typically 30-45 days from order confirmation, including rigorous QC testing before shipment to ensure zero-defect delivery.
Stay ahead with our latest market analysis and breakthroughs
Apr 24, 2026
Exploring the shift toward sustainable sources in pharmaceutical adjuvants and nutritional supplements.
Apr 17, 2026
Why Dexamethasone remains a critical molecule in modern medicine and its synergy with NSAID treatments.
Analysis of Lilly's oral GLP1 drug approval and its impact on the peptide supply chain route.
Read BreakthroughComprehensive pharmaceutical support for global healthcare providers
